NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Trial Profile

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Suspended
Phase of Trial: Phase II

Latest Information Update: 10 May 2018

At a glance

  • Drugs Ensartinib (Primary) ; Erdafitinib (Primary) ; Larotrectinib (Primary) ; LY 3023414 (Primary) ; Olaparib (Primary) ; Selumetinib (Primary) ; Tazemetostat (Primary) ; Vemurafenib (Primary)
  • Indications CNS cancer; Ewing's sarcoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Therapeutic Use
  • Acronyms Pediatric MATCH
  • Most Recent Events

    • 08 May 2018 According to an Epizyme media release, French National Agency for Medicines and Health Products Safety (ANSM) has put this trial on hold in first week of May 2018. The company is working with the regulatory authorities to resume enrollment in clinical trials.
    • 23 Apr 2018 According to an Epizyme media release, patients enrollment has been suspended in USA location, due to a safety report of a pediatric patient who developed a secondary lymphoma. Patients on study who have not experienced disease progression may continue to receive tazemetostat. The company has begun the modifications to resume this partial clinical hold in USA.
    • 23 Apr 2018 Status changed from recruiting to suspended, according to an Epizyme media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top